ETFs Vertex Pharmaceuticals Incorporated

VRTX

US92532F1003

Name	Weight	AuM	1st Jan change
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD	3.53%	1 M€	0.00%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED	2.32%	3 M€	-.--%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD	2.28%	6 M€	0.00%	-
LEVERAGE SHARES PLC - LS ARK GENOMIC REVOLUTION TRACKER ETP	1.93%	1 M€	+1.26%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	1.63%	21 M€	+4.14%	-
CSIF (IE) MSCI WORLD ESG LEADERS MINIMUM VOLATILITY BLUE UCITS ETF B - USD	1.61%	0 M€	-.--%	-
OSSIAM WORLD ESG MACHINE LEARNING UCITS ETF 1A - EUR	1.09%	0 M€	-.--%	-
DIREXION NASDAQ-100 EQUAL WEIGHTED ETF - USD	1.06%	1,034 M€	+10.24%	-
LEVERAGE SHARES 5X LONG NASDAQ 100 ETP - USD	0.73%	41 M€	0.00%	-
LEVERAGE SHARES -5X SHORT NASDAQ 100 ETP - USD	0.68%	5 M€	-65.53%	-
LEVERAGE SHARES PUBLIC LIMITED COMPANY - 3X LONG US TECH 100 ETP	0.68%	2 M€	-.--%	-
VANECK SUSTAINABLE WORLD EQUAL WEIGHT UCITS ETF - EUR	0.51%	908 M€	+2.18%	-

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (60.7%), Europe (31.3%) and other (8%).

Employees

6,100

Sector

Pharmaceuticals

Calendar

08-04 - Q2 2025 Earnings Release

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

479.53USD

Average target price

500.23USD

Spread / Average Target

+4.32%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 10/07/2025 BST			5-day change	1st Jan Change
479.53 ^USD	+0.12%		+4.92%	+19.08%

07-07	RBC Raises Price Target on Vertex Pharmaceuticals to $430 From $420, Keeps Sector Perform Rating	MT
07-03	Vertex Says Long-Term Data Show Casgevy's 'Durable' Clinical Benefits in Blood Disorder Trials	MT